Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.1.1.69 (
BMT
)
2,655
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Histidine-rich glycoprotein
(
HRGP
) is a potent inhibitor of T cell activation and production of cytokines such as (gamma-IFN). gamma-IFN released by activated T cells is increased during a short-term period at the onset of GvHD after allogeneic bone marrow transplantation. Therefore we investigated
HRGP
plasma levels in patients after
BMT
. Blood was collected from 20 children before and up to 6 weeks after
BMT
. In patients without GvHD,
HRGP
plasma levels decreased during the first week after
BMT
to 237 +/- 60 micrograms/ml, compared with 302 +/- 104 micrograms/ml before transplantation. However, no significant changes in mean
HRGP
plasma levels were observed during the following 5 weeks of the posttransplantation period. Acute GvHD occurred in 10 of 20 patients between the second and third week after
BMT
.
HRGP
levels (mean +/- SEM) in patients with GvHD dropped during the first week to 158 +/- 32 micrograms/ml, compared with pretransplant levels of 240 +/- 48 micrograms/ml). In contrast to results in patients without GvHD, a second and significant decrease was obtained between the second and third week after
BMT
in patients with GvHD (161 +/- 35 micrograms/ml vs 84 +/- 13 micrograms/ml; p < 0.01). In the third week after
BMT
,
HRGP
levels were significantly lower in patients with GvHD as compared with patients without GvHD (166 +/- 29 micrograms/ml; p < 0.01). The decrease in
HRGP
in the second and third posttransplantation week was not a result of steroid treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Correlation of low histidine rich glycoprotein plasma levels with the occurrence of acute graft-versus-host disease after allogeneic bone marrow transplantation. 763 87